Top Page
Oramed Pharm
(NASDAQ:ORMP)
Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)
Oramed Pharm Business Overview & Revenue Model
Oramed Pharm Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.00M | 0.00 | 1.34M | 2.70M | 2.70M | 2.71M |
| Gross Profit | -79.00K | -193.00K | 1.34M | 2.70M | 2.70M | 2.62M |
| EBITDA | 58.42M | -14.87M | 7.32M | -36.98M | -25.04M | -11.31M |
| Net Income | 43.85M | -19.10M | 5.53M | -37.76M | -22.24M | -11.51M |
Balance Sheet | ||||||
| Total Assets | 220.49M | 155.28M | 220.55M | 161.64M | 128.00M | 44.63M |
| Cash, Cash Equivalents and Short-Term Investments | 134.69M | 141.93M | 162.05M | 155.72M | 94.14M | 39.90M |
| Total Debt | 860.00K | 372.00K | 51.62M | 894.00K | 533.00K | 75.00K |
| Total Liabilities | 18.16M | 9.93M | 57.66M | 10.49M | 11.48M | 11.75M |
| Stockholders Equity | 203.28M | 146.26M | 163.82M | 151.81M | 115.77M | 32.88M |
Cash Flow | ||||||
| Free Cash Flow | -11.03M | -8.43M | -10.55M | -29.20M | -21.56M | -12.52M |
| Operating Cash Flow | -11.01M | -8.41M | -10.29M | -28.70M | -21.18M | -12.44M |
| Investing Cash Flow | 23.22M | 105.82M | -73.04M | 30.21M | -22.26M | 4.63M |
| Financing Cash Flow | -2.15M | -52.04M | 51.98M | 11.56M | 101.39M | 23.79M |
Oramed Pharm Technical Analysis
Oramed Pharm Risk Analysis
Oramed Pharm Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $135.33M | 3.40 | 24.38% | ― | ― | 814.20% | |
61 Neutral | $91.09M | -0.92 | -118.95% | ― | ― | 31.98% | |
56 Neutral | $135.73M | 21.21 | -13.82% | ― | -42.62% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $83.48M | -0.98 | -167.93% | ― | -90.18% | -17.93% | |
40 Underperform | $10.02M | ― | -247.78% | ― | ― | 2.26% |
Oramed Pharm Corporate Events
On January 12, 2026, Oramed Pharmaceuticals entered into a set of strategic agreements with Lifeward Ltd. under which Oramed will transfer its POD™ oral drug delivery platform, including its investigational oral insulin capsule, to Lifeward in exchange for Lifeward shares, pre-funded warrants, additional share purchase warrants and a 4% royalty on net revenue from Lifeward’s ReWalk personal exoskeleton franchise for up to 10 years or until other specified conditions are met. The structure of the deal, which remains subject to customary closing conditions and shareholder approvals, will make Oramed a significant shareholder with up to 49.9% beneficial ownership of Lifeward and gives it the ability to further increase its stake through senior secured convertible notes and associated warrants totaling up to $20 million in principal, most of which Oramed has agreed to purchase. Oramed will continue to manage the clinical trial program for the oral insulin candidate under a clinical trial management agreement, while Lifeward, a revenue-generating medical robotics company whose FDA-approved ReWalk and AlterG systems produced $26 million in sales over the last four reported quarters, will integrate the POD™ platform into its portfolio. The transaction effectively pivots Oramed from a pure-play oral drug delivery developer into a major strategic and financial stakeholder in a diversified medical robotics and drug-delivery business, while potentially providing Lifeward with both a new growth avenue in diabetes and additional capital aimed at driving the ReWalk and AlterG lines toward profitability.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
On January 7, 2026, Oramed Pharmaceuticals reported receiving an $18 million payment from Scilex Holdings Inc., marking full satisfaction of obligations under their Option Agreement and lifting Oramed’s realized returns on its original $99.5 million Scilex investment to $118 million. The company continues to hold a $27 million note and a $12 million convertible note in Scilex, along with warrants and a nine-year royalty interest, leaving further potential upside from the relationship and underscoring Oramed’s strategy of leveraging investment gains alongside its clinical operations. Reflecting these gains and surplus capital, Oramed’s board approved a cash dividend of $0.25 per share, expected to distribute about $10.5 million to shareholders on January 26, 2026, to investors of record as of January 16, 2026, signaling confidence in the company’s financial position and providing a direct return to equity holders.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
On December 31, 2025, Oramed Pharmaceuticals Inc. announced that board member Leonard Sank notified the company of his intention to resign from its board of directors, effective January 1, 2026, after serving 18 years with the company. The company stated that Sank’s departure was not due to any disagreement related to operations, policies or practices, signaling an orderly governance transition rather than a sign of internal conflict, though the exit of such a long‑tenured director may still mark a notable change in the board’s composition and institutional knowledge for stakeholders.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
On July 22, 2025, Oramed Pharmaceuticals Inc. entered into an option agreement with Scilex Holding Company granting Scilex the right to repurchase warrants held by Oramed to buy a total of 6,500,000 shares of Scilex common stock at a nominal exercise price, in two tranches, for an agreed aggregate purchase price of $27 million. Scilex repurchased the first tranche of warrants covering 3,130,000 shares on September 30, 2025 for $13 million following a $750,000 option fee, and on December 30, 2025 completed the second and final tranche for the remaining 3,370,000 warrants for $14 million, plus a further $750,000 option fee, resulting in Oramed receiving total cash proceeds of $28.5 million from the transaction, bolstering its liquidity and financial flexibility.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
On November 16, 2025, Oramed Pharmaceuticals’ Board of Directors declared a dividend of one common stock purchase right for each outstanding share of common stock, payable on November 27, 2025. This Rights Agreement is designed to protect shareholders in the event of a hostile takeover by ensuring fair treatment and enhancing the Board’s negotiation capabilities. The Rights become exercisable if a person or group acquires 15% or more of the company’s stock, allowing holders to purchase shares at a favorable rate, while the Rights held by the acquiring party become void. The Rights will expire three years after adoption unless redeemed or exchanged earlier.
On October 20, 2025, Oramed Pharmaceuticals repurchased and retired 1,155,367 shares from Hefei Tianhui Biotech Co., Ltd. for approximately $2.58 million. The joint venture with HTIT was terminated due to unmet financial conditions, but Oramed will continue its oral insulin program independently. The company has made significant investments in biomedical companies like Alpha Tau Medical, Scilex Holdings, and BioXcel Therapeutics, generating substantial returns and positioning itself for future growth. Oramed plans to reward shareholders with a one-time dividend and is actively pursuing new partnerships to expand its market potential.